NCT06493084View on ClinicalTrials.gov

Evaluate LAE102 in Healthy and Overweight/Obese Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

February 8, 2026

Conditions
Overweight and Obese Volunteers
Interventions
DRUG

LAE102 intravenous administration

A single dose of LAE102 administered intravenously

DRUG

placebo intravenous administration

A single dose of placebo administered intravenously

DRUG

LAE102 subcutaneous administration

Single dose of LAE102 administered subcutaneously

DRUG

placebo subcutaneous administration

single dose of placebo administered subcutaneously

DRUG

LAE102 multiple subcutaneous administration

Multiple dose of LAE102 administered subcutaneously

DRUG

Placebo multiple subcutaneous administration

Multiple dose of placebo administered subcutaneously

Trial Locations (1)

201203

RECRUITING

Fudan Zhongshan Hospital, Shanghai

All Listed Sponsors
lead

Laekna Limited

INDUSTRY